These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 9299482)
1. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein. Mori T; Shoemaker RH; Gulakowski RJ; Krepps BL; McMahon JB; Gustafson KR; Pannell LK; Boyd MR Biochem Biophys Res Commun; 1997 Sep; 238(1):218-22. PubMed ID: 9299482 [TBL] [Abstract][Full Text] [Related]
2. Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition. Barrientos LG; Matei E; Lasala F; Delgado R; Gronenborn AM Protein Eng Des Sel; 2006 Dec; 19(12):525-35. PubMed ID: 17012344 [TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of peptides that bind to cyanovirin-N, a potent human immunodeficiency virus-inactivating protein. Han Z; Simpson JT; Fivash MJ; Fisher R; Mori T Peptides; 2004 Apr; 25(4):551-61. PubMed ID: 15165709 [TBL] [Abstract][Full Text] [Related]
4. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage-displayed CV-N mutant library. Han Z; Xiong C; Mori T; Boyd MR Biochem Biophys Res Commun; 2002 Apr; 292(4):1036-43. PubMed ID: 11944919 [TBL] [Abstract][Full Text] [Related]
5. Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N). Gandhi MJ; Boyd MR; Yi L; Yang GG; Vyas GN Dev Biol (Basel); 2000; 102():141-8. PubMed ID: 10794101 [TBL] [Abstract][Full Text] [Related]
6. Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: characterization of low affinity carbohydrate binding site knockout mutants. Chang LC; Bewley CA J Mol Biol; 2002 Apr; 318(1):1-8. PubMed ID: 12054763 [TBL] [Abstract][Full Text] [Related]
7. Essential regions for antiviral activities of actinohivin, a sugar-binding anti-human immunodeficiency virus protein from an actinomycete. Takahashi A; Inokoshi J; Chiba H; Omura S; Tanaka H Arch Biochem Biophys; 2005 May; 437(2):233-40. PubMed ID: 15850563 [TBL] [Abstract][Full Text] [Related]
8. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. Mori T; Gustafson KR; Pannell LK; Shoemaker RH; Wu L; McMahon JB; Boyd MR Protein Expr Purif; 1998 Mar; 12(2):151-8. PubMed ID: 9518455 [TBL] [Abstract][Full Text] [Related]
9. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum. Gustafson KR; Sowder RC; Henderson LE; Cardellina JH; McMahon JB; Rajamani U; Pannell LK; Boyd MR Biochem Biophys Res Commun; 1997 Sep; 238(1):223-8. PubMed ID: 9299483 [TBL] [Abstract][Full Text] [Related]
10. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. Mariner JM; McMahon JB; O'Keefe BR; Nagashima K; Boyd MR Biochem Biophys Res Commun; 1998 Jul; 248(3):841-5. PubMed ID: 9704015 [TBL] [Abstract][Full Text] [Related]
14. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Mori T; Boyd MR Antimicrob Agents Chemother; 2001 Mar; 45(3):664-72. PubMed ID: 11181340 [TBL] [Abstract][Full Text] [Related]
15. A monovalent mutant of cyanovirin-N provides insight into the role of multiple interactions with gp120 for antiviral activity. Fromme R; Katiliene Z; Giomarelli B; Bogani F; Mc Mahon J; Mori T; Fromme P; Ghirlanda G Biochemistry; 2007 Aug; 46(32):9199-207. PubMed ID: 17636873 [TBL] [Abstract][Full Text] [Related]
16. PEGylation of cyanovirin-N, an entry inhibitor of HIV. Zappe H; Snell ME; Bossard MJ Adv Drug Deliv Rev; 2008 Jan; 60(1):79-87. PubMed ID: 17884238 [TBL] [Abstract][Full Text] [Related]
17. Flipping the switch from monomeric to dimeric CV-N has little effect on antiviral activity. Barrientos LG; Lasala F; Delgado R; Sanchez A; Gronenborn AM Structure; 2004 Oct; 12(10):1799-807. PubMed ID: 15458629 [TBL] [Abstract][Full Text] [Related]
18. Atomic mapping of the interactions between the antiviral agent cyanovirin-N and oligomannosides by saturation-transfer difference NMR. Sandström C; Berteau O; Gemma E; Oscarson S; Kenne L; Gronenborn AM Biochemistry; 2004 Nov; 43(44):13926-31. PubMed ID: 15518540 [TBL] [Abstract][Full Text] [Related]
19. Domain-swapped structure of a mutant of cyanovirin-N. Botos I; Mori T; Cartner LK; Boyd MR; Wlodawer A Biochem Biophys Res Commun; 2002 May; 294(1):184-90. PubMed ID: 12054761 [TBL] [Abstract][Full Text] [Related]
20. Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A. Witvrouw M; Fikkert V; Hantson A; Pannecouque C; O'keefe BR; McMahon J; Stamatatos L; de Clercq E; Bolmstedt A J Virol; 2005 Jun; 79(12):7777-84. PubMed ID: 15919930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]